Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy
Allogeneic Therapy Can Be Re-Dosed
Nkarta has updated its early results for its natural killer cell therapy, where it has shown promising efficacy and potentially superior safety to existing CAR-Ts.
You may also be interested in...
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
Editas is seen as a slow developer in the CRISPR-based therapeutics field compared with its rivals but its new CEO has unveiled a new strategy to speed progress.
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.